Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: An immunohistochemical study

Journal of Dermatological Treatment

Volumn 21, Issue 1, 2010, Pages 13-22

  Van Der Velden, Haike M J ^a   Pasch, Marcel C ^a   Van Erp, Piet E J ^a   Van Lingen, Rosanne G ^a   Otero, Marisol E ^a   De Boer Van Huizen, Roelie T ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Betamethasone dipropionate; Calcipotriol; Epidermal proliferation and differentiation; Human beta defensin 2; Immunohistochemistry; T lymphocytes

Indexed keywords

BETA DEFENSIN 2; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CYTOKERATIN 15; KI 67 ANTIGEN; TACLONEX; UNCLASSIFIED DRUG; BETAMETHASONE; BETAMETHASONE DIPROPIONATE, CALCIPOTRIOL DRUG COMBINATION; BIOLOGICAL MARKER; CALCITRIOL; DERMATOLOGICAL AGENT; DRUG COMBINATION;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; SKIN INFLAMMATION; T LYMPHOCYTE; ADOLESCENT; ANALOGS AND DERIVATIVES; DRUG COMBINATION; EPITHELIUM; METABOLISM; PATHOLOGY; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BETAMETHASONE; BIOLOGICAL MARKERS; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EPITHELIUM; HUMANS; PSORIASIS; TREATMENT OUTCOME; YOUNG ADULT; BIOMARKERS;

EID: 76749148215     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903214175     Document Type: Article

References (64)

1. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin Ja, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: A population-based study. Arch Dermatol. 2005;141:1537-1541.
2. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: Results from a population-based study. J Am Acad Dermatol. 2005;52:23-26.
3. Kavli G, Stenvold SE, vandbakk O. Low prevalence of psoriasis in Norwegian lapps. Acta Derm Venereol. 1985;65:262-263.
4. Kavli G, forde OH, Arnesen E, Stenvold SE. Psoriasis: Familial predisposition and environmental factors. Br Med J (clin Res Ed). 1985;291:999-1000.
5. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
6. Ashcroft DM, Li Wan PA, Griffths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther. 2000;25:1-10.
7. Van de Kerkhof PCM, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2003;16: 69-83.
8. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352: 1899-1912.
9. Peeters P, Ortonne JP, Sitbon R, Guignard E. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology. 2005;211: 139-145.
10. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Treatment of psoriasis in the Nordic countries: A questionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study. Acta Derm Venereol. 2001;81:116-121.
11. Van de Kerkhof PCM, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, et al. Safety and effcacy of combined high-dose treatment with calcipotriol ointment and solution in patients with psoriasis. Dermatology. 2002;204:214-221.
12. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol. 1989;125:1647-1652.
13. Kragballe K, Fogh K, Sogaard H. Long-term effcacy and tolerability of topical calcipotriol in psoriasis. results of an open study. Acta Derm Venereol. 1991;71:475-478.
14. Kragballe K, Barnes L, Hamberg KJ, Hutchinson P, Murphy F, Moller S, et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: Tolerability and effcacy. Br J Dermatol. 1998;139:649-654.
15. Glade CP, van Erp PE, van de Kerkhof PCM. Epidermal cell DNA content and intermediate flaments keratin 10 and vimentin after treatment of psoriasis with calcipotriol cream once daily, twice daily and in combination with clobetasone 17-butyrate cream or betamethasone 17-valerate cream: A comparative fow cytometric study. Br J Dermatol. 1996;135: 379-384.
16. Ruzicka T, Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: A multicentre, double-blind, randomized study. Br J Dermatol. 1998;138:254-258.
17. Kragballe K, Wildfang IL. Calcipotriol (Mc 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282:164-167.
18. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37: 889-895.
19. De Mare S, de Jong EMGJ, van de Kerkhof PCM. DNA content and Ks8.12 binding of the psoriatic lesion during treatment with the vitamin D3 analogue MC903 and betamethasone. Br J Dermatol. 1990;123:291-295.
20. Berth-Jones J, fletcher A, Hutchinson PE. epidermal cytokeratin and immunocyte responses during treatment of psoriasis with calcipotriol and betamethasone valerate. Br J Dermatol. 1992;126:356-361.
21. De Jong EMGJ, van de Kerkhof PCM. Simultaneous assessment of infammation and epidermal proliferation in psoriatic plaques during long-term treatment with the vitamin D3 analogue MC903: Modulations and interrelations. Br J Dermatol. 1991;124:221-229.
22. Reichrath J, Muller SM, Kerber A, Baum HP, Bahmer FA. Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol. 1997;36:19-28.
23. Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Similarly potent action of 1, 25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci. 2003;31:21-28.
24. Van der vleuten CJM, de Jong EMGJ, van de Kerkhof PCM. Epidermal differentiation characteristics of the psoriatic plaque during treatment with calcipotriol. Arch Dermatol Res. 1996;288:366-372.
25. Nieboer C, verburgh CA. Psoriasis treatment with vitamin D3 analogue Mc 903. Br J Dermatol. 1992;126:302-303.
26. Jensen AM, Llado MB, Skov L, Hansen ER, Larsen JK, Baadsgaard O. calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol. 1998;139: 984-991.
27. KÖrver JE, Vissers WH, van Rens DW, Pasch MC, van Erp PE, Boezeman JB, et al. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol. 2007;156:130-137.
28. Kraft N, thomson NM, atkins RC. Modulation of inhibition of the human mitogen response by methylprednisolone. Transplantation. 1979;28:275-279.
29. Hirschberg H, Hirschberg T, Nousiainen H, Braathen LR, Jaffe E. The effects of corticosteroids on the antigen presenting properties of human monocytes and endothelial cells. Clin Immunol Immunopathol. 1982;23:577-585.
30. Gerrard TL, cupps TR, Jurgensen CH, Fauci AS. Hydrocortisone-mediated inhibition of monocyte antigen presentation: Dissociation of inhibitory effect and expression of DR antigens. cell Immunol. 1984;85:330-339.
31. Ashworth J, Booker J, Breathnach SM. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br J Dermatol. 1988;118:457-469.
32. Belsito DV, Flotte TJ, Lim HW, Baer RL, thorbecke GJ, Gigli I. Effect of glucocorticosteroids on epidermal Langerhans cells. J Exp Med. 1982;155:291-302.
33. Rhodes J, Ivanyi J, Cozens P. Antigen presentation by human monocytes: Effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur J Immunol. 1986;16:370-375.
34. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol. 1982;129:1803-1805.
35. Kang S, Yi S, Griffths CE, Fancher L, Hamilton TA, choi JH. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol. 1998;138:77-83.
36. Vissers WH, Berends M, Muys L, van Erp PE, de Jong EMGJ, van de Kerkhof PCM. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol. 2004;13:106-112.
37. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol. 2002;82:131-135.
38. Guenther L, Cambazard F, van de Kerkhof PCM, Snellman E, Kragballe K, Chu AC, et al. Effcacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: A randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147: 316-323.
39. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205: 389-393.
40. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and effcacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48:48-54.
41. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, et al. Effcacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol. 2004;150:1167-1173.
42. Ortonne JP, Kaufmann R, Lecha M, Goodfeld M. Effcacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology. 2004;209:308-313.
43. Kragballe K, van de Kerkhof PCM. Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2006;20: 39-44.
44. van der Velden HMJ, van de Kerkhof PCM, Pasch MC, de Boer-van Huizen RT, van Lingen RG, Erp PE. The universal detection of antigens from one skin biopsy specimen. J Cutan Pathol. 2009;36:972-979.
45. Ruifrok AC, Johnston DA. Quantifcation of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291-299.
46. Van Lingen RG, Poll MK, Seyger MM, de Jong EMGJ, Van de Kerkhof PCM, van Erp PE. Distribution of dipeptidylpeptidase Iv on keratinocytes in the margin zone of a psoriatic lesion: A comparison with hyperproliferation and aberrant differentiation markers. Arch Dermatol Res. 2008;300:561-567.
47. Van Duijnhoven MW, van de Kerkhof PCM, Pasch MC, Muys L, van erp PE. The combination of the zenon labeling technique and microscopic image analysis to study cell populations in normal and psoriatic epidermis. J Cutan Pathol. 2005;32:212-219.
48. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defned by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
49. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
50. Van rossum MM, van Erp PE, van de Kerkhof PCM. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: A fow cytometric study. Dermatology. 2001;203:148-152.
51. Waseem A, Dogan B, tidman N, alam Y, Purkis P, Jackson S, et al. Keratin 15 expression in stratifed epithelia: Down-regulation in activated keratinocytes. J Invest Dermatol. 1999;112:362-369.
52. Castelijns FA, Gerritsen MJ, van Erp PE, van de Kerkhof PCM. Immunohistochemical assessment of keratin 16 on paraffn-embedded sections of normal and hyperproliferative skin: Monoclonal antibodies Ks8.12 and LL025 in a comparative study. Arch Dermatol res. 1999;291:59-63.
53. Leigh IM, Navsaria H, Purkis PE, McKay IA, Bowden PE, Riddle PN. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol. 1995;133:501-511.
54. Weiss RA, Eichner R, Sun TT. Monoclonal antibody analysis of keratin expression in epidermal diseases: A 48- and 56-kdalton keratin as molecular markers for hyperproliferative keratinocytes. J Cell Biol. 1984;98:1397-1406.
55. Van Lingen RG, van de Kerkhof PCM, Seyger MM, de Jong EMGJ, Rens DW, Poll MK, et al. CD26/dipeptidylpeptidase Iv in psoriatic skin: Upregulation and topographical changes. Br J Dermatol. 2008;158:1264-1272.
56. Novelli M, Savoia P, fierro MT, Verrone A, Quaglino P, Bernengo MG. Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases. Br J Dermatol. 1996;134:1052-1056.
57. Savoia P, Novelli M, de Matteis A, Verrone A, Bernengo MG. Effects of topical calcipotriol on the expression of adhesion molecules in psoriasis. J Cutan Pathol. 1998;25:89-94.
58. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347: 1151-1160.
59. Huh WK, Oono T, Shirafuji Y, Akiyama H, Arata J, Sakaguchi M, et al. Dynamic alteration of human beta-defensin 2 localization from cytoplasm to intercellular space in psoriatic skin. J Mol Med. 2002;80:678-684.
60. Liu L, Wang L, Jia HP, Zhao C, Heng HH, Schutte BC, et al. Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of infammation. Gene 1998;222:237-244.
61. Liu AY, Destoumieux D, Wong AV, Park CH, valore EV, Liu L, et al. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol. 2002;118:275-281.
62. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic from human skin. Nature. 1997;387:861.
63. Pernet I, Reymermier C, Guezennec A, Branka JE, Guesnet J, Perrier E, et al. Calcium triggers beta-defensin (hBD-2 and hBD-3) and chemokine macrophage infammatory protein-3 alpha (MIP-3alpha/ccL20) expression in monolayers of activated human keratinocytes. Exp Dermatol. 2003;12: 755-760.
64. Harder J, Meyer-Hoffert U, Wehkamp K, Schwichtenberg L, Schroder JM. Differential gene induction of human betadefensins (hBD-1, -2, -3, and -4) in keratinocytes is inhibited by retinoic acid. J Invest Dermatol. 2004;123:522-529.